Recurrent Ovarian Cancer: When and How to Treat

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Oncology Reports

• Publication date

  2011-11-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11912-011-0199-3PMID 22045509
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.

  2013cited by this paper
• Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

  2011cited by this paper
• Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-institution experience.

  2011cited by this paper
• OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.

  2011cited by this paper
• Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study

  2011cited by this paper
• Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

  2011cited by this paper
• A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.

  2011cited by this paper
• Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

  2011cited by this paper
• Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer

  2011cited by this paper
• An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer.

  2011cited by this paper
• A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

  2011cited by this paper
• Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.

  2010cited by this paper
• PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

  2010cited by this paper
• A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.

  2010cited by this paper
• Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

  2010cited by this paper
• A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.

  2010cited by this paper
• Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

  2010cited by this paper
• Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.

  2010cited by this paper
• Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?

  2010cited by this paper
• 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.

  2010cited by this paper
• Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

  2010cited by this paper
• Making the best of PARP inhibitors in ovarian cancer

  2010cited by this paper
• Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation.

  2010cited by this paper
• Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.

  2010cited by this paper
• Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells

  2010cited by this paper
• Tamoxifen for relapse of ovarian cancer.

  2010cited by this paper
• Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.

  2010cited by this paper
• Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?

  2010cited by this paper
• Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer

  2010cited by this paper
• Weekly paclitaxel in the treatment of recurrent ovarian cancer

  2010influential reference
• Randomized Phase III Study of Canfosfamide in Combination With Pegylated Liposomal Doxorubicin Compared With Pegylated Liposomal Doxorubicin Alone in Platinum-Resistant Ovarian Cancer

  2010cited by this paper
• Are Surveillance Procedures of Clinical Benefit for Patients Treated for Ovarian Cancer?: A Retrospective Italian Multicentric Study

  2009cited by this paper
• Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (A

  2009cited by this paper
• Surgery for Recurrent Ovarian Cancer: Role of Peritoneal Carcinomatosis: Exploratory Analysis of the DESKTOP I Trial About Risk Factors, Surgical Implications, and Prognostic Value of Peritoneal Carcinomatosis

  2009cited by this paper
• Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.

  2009cited by this paper
• Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

  2009cited by this paper
• What Is the Benefit of Bevacizumab Combined with Chemotherapy in Patients with Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Malignancies?

  2009cited by this paper
• Antiangiogenic drugs in ovarian cancer

  2009cited by this paper
• The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer.

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).

  2009cited by this paper
• MedScape

  2009cited by this paper
• Surveillance of patients after initial treatment of ovarian cancer.

  2009cited by this paper
• Hypersensitivity reactions to antineoplastic agents: an overview

  2009cited by this paper
• Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.

  2009cited by this paper
• Symptom Control in Patients With Recurrent Ovarian Cancer: Measuring the Benefit of Palliative Chemotherapy in Women With Platinum Refractory/Resistant Ovarian Cancer

  2009cited by this paper
• The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project.

  2009cited by this paper
• Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels.

  2009cited by this paper
• Epithelial Ovarian Cancer: Role of Pegylated Liposomal Doxorubicin in Prolonging the Platinum-Free Interval and Cancer Antigen 125 Trends During Treatment

  2009cited by this paper
• Antiangiogenic drugs in ovarian cancer

  2008cited by this paper
• Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.

  2008cited by this paper
• Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.

  2008cited by this paper
• Late congestive heart failure after hematopoietic cell transplantation.

  2008cited by this paper
• Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.

  2008cited by this paper
• The role of regular physical examination in the detection of ovarian cancer recurrence.

  2008influential reference
• Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

  2008cited by this paper
• Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

  2008cited by this paper
• Randomized pilot trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer: preliminary data

  2008cited by this paper
• Phase II trial of fulvestrant in the treatment of recurrent ovarian carcinoma

  2008cited by this paper
• Preoperative diagnosis of ovarian malignancy—preliminary results of the use of three-dimensional vascular ultrasound

  2008cited by this paper
• Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

  2008cited by this paper
• Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

  2007cited by this paper
• Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.

  2007cited by this paper
• Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

  2007cited by this paper
• Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.

  2007cited by this paper
• Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.

  2007cited by this paper
• A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

  2007cited by this paper
• Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: Initial results of a phase II study

  2007cited by this paper
• Aromatase inhibitors in gynecologic cancers.

  2007cited by this paper
• Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.

  2007cited by this paper
• What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

  2007cited by this paper
• Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006influential reference
• Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer.

  2006cited by this paper
• Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.

  2006cited by this paper
• Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

  2005cited by this paper
• Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study

  2005cited by this paper
• Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.

  2005cited by this paper
• What is the role of dose-dense therapy?

  2005cited by this paper
• Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

  2005cited by this paper
• The anti-angiogenic basis of metronomic chemotherapy

  2004cited by this paper
• Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance

  2004cited by this paper
• Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation.

  2003cited by this paper
• Oral Etoposide (VP16) in Platinum-Resistant Epithelial Ovarian Cancer (EOC)

  2003cited by this paper
• A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.

  2003cited by this paper
• Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.

  2003cited by this paper
• Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

  2003influential reference
• Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation☆

  2003cited by this paper
• No rules without exception: long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer.

  2002cited by this paper
• Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels.

  2002cited by this paper
• Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study

  2002influential reference
• Peritoneal metastases: detection with spiral CT in patients with ovarian cancer.

  2002cited by this paper
• Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum.

  2001cited by this paper
• Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.

  2001cited by this paper
• Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels.

  2001cited by this paper

• Preoperative CECT-Based Multitask Model Predicts Peritoneal Recurrence and Disease-Free Survival in Advanced Ovarian Cancer: A Multicenter Study.

  2024cites this paper
• ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ ĐIỀU TRỊ UNG THƯ BIỂU MÔ BUỒNG TRỨNG TÁI PHÁT TẠI BỆNH VIỆN TỪ DŨ

  2024cites this paper
• British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024.

  2024cites this paper
• Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer

  2023cites this paper
• Diagnostic and prognostic values of MMP-9 expression in ovarian cancer: A study based on bioinformatics analysis and meta-analysis

  2022cites this paper
• Real-world experience with trabectedin for the treatment of recurrent ovarian cancer

  2021cites this paper
• British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice 2017

  2021cites this paper
• Raised CA125 – what we actually know…

  2020cites this paper
• Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy

  2020cites this paper
• Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.

  2019cites this paper
• Phosphorylated retinoblastoma is a biomarker of overall disease control and better progression-free survival of recurrent epithelial ovarian cancer patients treated with second-line topoisomerase inhibitor CPT-11 chemotherapy

  2018cites this paper
• Trabectedin in Ovarian Cancer: is it now a Standard of Care?

  2018cites this paper
• British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.

  2017cites this paper
• Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

  2017cites this paper
• Prophylactic 3-hour graduated infusion schedule minimizes risk of carboplatin hypersensitivity reactions - A prospective study.

  2017cites this paper
• Long-term Benefit of Tumor Volume-Directed Involved Field Radiation Therapy in the Management of Recurrent Ovarian Cancer

  2016cites this paper
• miR-29B regulates cell proliferation and invasion in human ovarian clear cell carcinoma by targeting lysyl oxidase (LOX)

  2016cites this paper
• Impact of Olaparib for Maintenance Monotherapy on Survival in Breast and Ovarian Cancer: A Systematic Review and Pooled Analysis of Published Trials

  2015cites this paper
• Roles of Cx43 and AKAP95 in ovarian cancer tissues in G1/S phase.

  2015cites this paper
• Roles of Cx 43 and AKAP 95 in ovarian cancer tissues in G 1 / S phase

  2015cites this paper
• Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer

  2015cites this paper
• Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment.

  2014cites this paper
• The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer

  2014cites this paper
• Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin.

  2014cites this paper
• Biochemical markers for screening of ovarian cancer

  2013cites this paper
• LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.

  2013cites this paper
• PET/CT in gynecologic malignancies.

  2013cites this paper
• Natural history of epithelial ovarian cancer and its relation to surgical and medical treatment

  2013cites this paper
• Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib

  2013cites this paper
• Malignant ascites: pathophysiology and treatment

  2013cites this paper
• Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib

  2013cites this paper
• Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib

  2013cites this paper
• Systemic treatment for recurrent epithelial ovarian cancer

  2013cites this paper
• Association between Lysyl Oxidase G473A Polymorphism and Ovarian Cancer in the Han Chinese Population

  2012cites this paper
• Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.

  2012cites this paper